turn stimulate the release of prostaglandins, molecules that mediate the signs and symptoms of illness (somnolence, fatigue and fever) by acting on the hypothalamus 11 . An important aspect of mediators of inflammation in the circulation is the activation of the complement system, which mediates microbial opsonization and killing, and generates inflammatory peptides such as C3a and C5a 12 .
Basic elements of resolution
Mechanisms that shut down the inflammatory response have paramount importance in the return to homeostasis (Fig. 2) . Resolution is not simply the elimination of the stressing agent but instead is an active process involving functional reprogramming of cells through ad hoc production of mediators. Several mechanisms inhibit inflammation. The cytokine IL-10 suppresses the production of proinflammatory cytokines 13 and is mainly derived from regulatory T cells. IL-37, a member of the IL-1 family, broadly suppresses inflammation, as does the cytokine TGF-b, which is released from monocytes and platelets 14 . Cleaved extracellular domains of cytokine receptors, such as soluble TNFR and IL-1R, serve as decoy receptors and limit inflammation by binding and neutralizing their respective cytokines. Receptor antagonists, such as IL-1Ra, bind IL-1R without inducing an intracellular signal, thus inhibiting the biological activity of the interleukins IL-1a and IL-1b (ref. 15) . Complement inhibitors also modulate inflammation 16 , and prostaglandins and lipid mediators such as resolvins patterns) or endogenous stress signals (danger-associated molecular patterns) through germline-encoded pattern-recognition receptors (PRRs) 3 . PRRs are mainly expressed by myeloid cells, such as monocytes, macrophages, neutrophils and dendritic cells, but are also expressed by lymphocytes, fibroblasts and epithelial cells 4 . Cellular stimulation triggers inflammatory processes through the release of proinflammatory cytokines and chemokines. The cytokines TNF and IL-1b have autocrine and paracrine effects leading to the local activation of macrophages and neutrophils, but when these cytokines are released in large amounts, they can exert endocrine effects, such as induction of acute-phase proteins in the liver, platelet activation, fever, fatigue and anorexia. Cytokines activate endothelial cells, thus increasing vascular permeability and facilitating entrance of immune cells into tissues at the site of infection, but they can also lead to capillary leakage, vasodilation and hypotension 5, 6 (Fig. 1) . The main function of chemokines is to recruit additional immune cells to the site of infection 7 ; these cells include neutrophils, which exert a crucial role in the phagocytosis and killing of pathogens 8, 9 . The cytokine IFN-g, derived from type 1 helper T cells (T H 1 cells), activates neutrophils, whereas the cytokine IL-22, derived from IL-17-producing helper T cells (T H 17 cells) and innate lymphoid cells, acts on epithelial cells and subsequently stimulates the production and release of antimicrobial peptides, including defensins 10 .
In the bloodstream, activated monocytes and neutrophils release cytokines, which in I nflammation is viewed as the driving factor in many diseases, including atherosclerosis, cancer, autoimmunity and infections 1 , and it is a major contributor to age-related conditions 2 . The classical definition of inflammation-comprising rubor (redness), calor (warmth), dolor (pain) and tumor (swelling), as described by Celsus (30 bc-38 ad), and functio laesa (loss of function), as added by Galen (129-210 ad)-has persisted in modern times. Functionally, inflammation is broadly defined as a protective response of the organism to stimulation by invading pathogens or endogenous signals such as damaged cells, thus resulting in the elimination of the initial cause of injury, the clearance of necrotic cells and tissue repair. However, owing to the complex and often simultaneous molecular, immunological and physiological processes involved in the inflammatory response, clearly defining inflammation presents a challenge. Here, we provide a guide to the sequence of events initiated during inflammation ( Fig. 1) and the main mechanisms leading to the resolution of inflammation (Fig. 2) , and we include an overview of the most important characteristics of the inflammatory process in various tissues and diseases (Table 1) .
Basic elements of inflammation
Inflammation is induced when host cells sense evolutionarily conserved structures on pathogens (pathogen-associated molecular pathogens to the primary site of infection, whereas systemic activation may result in disseminated intravascular coagulation, microvascular thrombosis and bleeding 22 (Table 1) . Enhanced adherence of leukocytes and platelets to the endothelial surface, and subsequent transmigration, results in vascular inflammation and disruption of the endothelial-cell barrier, thus causing leakage of intravascular proteins into the extravascular space, tissue edema and decreased microvascular perfusion. When severe, these abnormalities may lead to organ dysfunction and even death 23 .
Acute intestinal inflammation
Acute intestinal inflammation is protective by eliminating infectious, toxic and other injurious agents, while initiating the process of repair. Chronic inflammation in the gastrointestinal tract results from repeated acute injury and/ or impaired resolution of inflammation, thus leading to conditions such as chronic gastritis and peptic ulcer disease, chronic pancreatitis, vulnerable to secondary infections 19 .
Here, we provide an up-to-date guide to inflammation and summarize the main features of acute or chronic inflammation in specific human diseases ( Table 1) .
Sepsis
In sepsis, the release of danger-associated molecular patterns or alarmins from injured host cells activates PRRs, which also recognize pathogen-associated molecular patterns, thus giving rise to a vicious cycle of sustained hyperinflammation 20 . However, an ineffective antimicrobial host defense often accompanies this condition. Proinflammatory cytokines produced after recognition of the invading pathogens by PRRs 21 can help protect the host but also can promote tissue injury during overwhelming sepsis. Unrestrained activation of complement contributes to organ failure, and C5a blockade improves the outcome of experimental sepsis. Local activation of the coagulation system in sepsis helps to confine exert negative feedback loops by suppressing the transcription and release of cytokines. Acute-phase proteins induced during inflammation, such as a-1 antitrypsin, have broad anti-inflammatory properties 17 . Additional anti-inflammatory mechanisms involve stress hormones, particularly corticosteroids and catecholamines; negative regulators of Tolllike-receptor signaling, such as IRAK-M and A20; and microRNAs, such as miR-146 or miR-125. Neuroimmunoregulatory mechanisms (the so-called immunological reflex) provide anti-inflammatory negative feedback, which is triggered by peripheral sensory input transmitted through the afferent vagus nerve to the brainstem and is followed by activation of the efferent vagus and splenic nerve 18 , release of norepinephrine in the spleen and secretion of acetylcholine by a subset of CD4 + T cells, thereby inhibiting production of proinflammatory cytokines by macrophages. However, an anti-inflammatory response that is too pronounced or persistent may render the host The immunological mechanisms leading to the induction of inflammation during the first stages of host defense against invading pathogens. AAT, a1-antitrypsin; PAMPs, pathogen-associated molecular patterns; AMPs, antimicrobial peptides; DAMPs, danger-associated molecular patterns; MAC, membrane attack complex; ROS, reactive oxygen species; CRP, C-reactive protein; MBL, mannose-binding lectin; Mf, macrophage or monocyte; CCL, C-Cmotif chemokine ligand.
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C O M M E N T Diabetes
Type I diabetes (10% of people with diabetes) is caused by immunologically mediated selective beta-cell destruction triggered by unknown environmental factors in individuals with a polygenetic predisposition. Inflammation plays a crucial role in this process, whose first stepthe appearance of inflammatory macrophages and proinflammatory cytokines, particularly IL-1b and TNF, in the islet-cell infiltratecontributes to beta-cell toxicity. Subsequently, a lymphocytic infiltrate develops, including populations of CD8 + and CD4 + T cells displaying autoreactivity against specific islet antigenic peptides. The T cells are often accompanied by an influx of CD20 + B cells. Despite the promising initial results found in small studies, the use of antagonists of IL-1 or TNF to improve insulin secretion in people with new-onset type I diabetes has not been successful in phase II trials 37, 38 . Type II diabetes (T2D; 90% of cases) is characterized by defective insulin secretion as well as a decreased response to insulin. IL-1b-driven inflammation plays an important role in the beta-cell loss in T2D. Insulin resistance in T2D is also due to inflammation of liver and fat tissues through general inflammatory pathways as described above, and activation of the IL-1b-inflammasome pathway plays a crucial role ( Table 1) . Clinical trials using IL-1Ra, antibodies to IL-1b and salsalate 39, 40 have offered a proof of concept of a beneficial effect of dampening inflammation in T2D.
Lung disease
Innate inflammation and adaptive immunity are essential to lung defense; however, if unchecked, they result in lung disease. Air pollutants with inflammatory effects, including vascular inflammation. Statins (inhibitors of HMG-CoA reductase, an enzyme involved in cholesterol synthesis) have proven remarkably successful in preventing first and recurrent cardiovascular events and in decreasing levels of both cholesterol and high-sensitivity C-reactive protein. Clinical trials are currently evaluating whether anti-inflammatory agents such as low-dose methotrexate and canakinumab (a monoclonal antibody targeting IL-1b) could prevent atherosclerotic events.
Neurodegenerative diseases
Innate immunological mechanisms are emerging as crucial components of normal brain aging as well as major contributors to neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis 31, 32 . Several mutations in genes encoding immune proteins increase the risk of developing Alzheimer's disease (TREM2, CD33 and PLCG2), amyotrophic lateral sclerosis (C9orf72, TBK1 and CHCHD10) and Parkinson's disease (LRRK2) ( Table 1) . Activation of microglia in response to b-sheetstructured proteins, misfolded proteins, neuronal debris or aberrant nucleic acids 33 triggers neuronal dysfunction, structural damage and ultimately cell death. b-amyloid fibrils, a major pathological hallmark of Alzheimer's disease, induce the activation of the NLRP3 inflammasome and the generation of IL-1b in microglia through activation of various PRRs 34 . Microglia express receptors for neurotransmitters and neurotrophins in a brainregion-specific manner. Norepinephrine and acetylcholine suppress excess inflammation in the brain 35 .
Liver diseases
Mediators of inflammation, particularly cytokines such as IL-1 family cytokines, IL-6 and TNF, are associated with acute liver failure, the hepatic acute-phase response, steatosis, cholestasis, hypergammaglobulinemia and the development of fibrosis 36 . In acute injury, hepatic inflammatory cytokines induce necrosis of hepatocytes but also mediate hepatocyte regeneration. Hepatocyte necrosis releases IL-1a, which recruits bone-marrow-derived monocytes and macrophages. Macrophages are also rapidly recruited from the peritoneum, and they appear to have protective effects. Fibrosis and the release of TGF-b play crucial roles in chronic liver disease. Alcoholic and nonalcoholic fatty liver disease are characterized by sterile inflammation with massive lipid accumulation. Anti-inflammatory strategies have not yet been adequately developed in the management of these disorders. celiac disease and inflammatory bowel disease. In Crohn's disease and ulcerative colitis, although the precise etiology is unknown, treatment aims to dampen inflammation and its consequences 24 . Corticosteroids decrease inflammatory flares but in most cases do not maintain remission. Immunosuppressants are also effective but do not represent a definitive cure. Such immunosuppressants include azathioprine and methotrexate, monoclonal antibodies against TNF, IL-12 or IL-23, and monoclonal antibodies against a 4 b 7 integrin, a protein complex that promotes leukocyte trafficking specifically into the gastrointestinal tract.
Rheumatoid arthritis
Rheumatoid arthritis, an autoimmune disease involving severe joint inflammation, cartilage and bone destruction, is strongly associated with the presence of autoantibodies, such as rheumatoid factor and anti-citrullinatedpeptide antibodies 25 27 . IL-1b and IL-17A induce destruction of cartilage and bone, the latter through the activation of osteoclasts by the cytokine RANKL ( Table 1) . Anti-TNF monoclonal antibodies or IL-1Ra, anti-IL-6R, anti-IL-12p40 or anti-IL-17A can treat rheumatoid arthritis 26 . Small-molecule inhibitors of the Jak-STAT signaling pathway downstream of inflammatory-cytokine receptors have shown efficacy in subsets of patients.
Atherosclerosis
Atherosclerosis is characterized by a strong activation of endothelial cells in the inner lining of the arterial lumen; these cells recruit monocytes via the expression of adhesion molecules. Monocytes mature into macrophages that replicate 28 Figure 2 The regulatory mechanisms that modulate inflammation and lead to resolution after the elimination of invading pathogens. AAT, a1-antitrypsin; IL-1R1 and IL-1R2, IL-1R type I and type II, respectively; sTNFR, soluble TNFR; TNFR I/II, TNFR types I and II; PGE 2 , prostaglandin E2; Mf, macrophage or monocyte; T reg , regulatory T cell.
Debbie Maizels/Springer Nature • Low-grade innate inflammation in adipose tissue, liver and islets; insulin resistance and beta-cell apoptosis in T2D
• Proinflammatory cytokines IL-1b and TNF
• In T1D, also T cell-mediated beta-cell killing
•Macrovascular complications (myocardial infarction, stroke, claudication)
•Microvascular complications (kidney, ocular, neuronal)
• Anti-IL-1 (anakinra, canakinumab)
• • Immunostimulatory: BCG, muramyl dipeptide (mifamurtide), b-glucan FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulinemia D and periodic fever syndrome; HS, hidradenitis suppurativa; hsCRP, high-sensitivity C-reactive protein; T1D, type I diabetes; COPD, chronic obstructive pulmonary disease; BCG, Mycobacterium bovis bacillus Calmette-Guerin; GM-CSF, granulocyte-macrophage colony-stimulating factor; r, recombinant.
C O M M E N T
components and functions downstream of IL-1 in mouse models of carcinogenesis ( Table 1) . The type of inflammatory reaction determines the clinical severity of cancer. T cell-driven inflammation, characterized by an interferon signature, is associated with a better prognosis 54 , whereas high macrophage infiltration is generally associated with poorer prognosis, especially when markers of type 2 polarization are considered 53 .
Conclusions and future perspectives
The heterogeneous nature of the inflammatory response depends on the type of disease and the organ in which it occurs, and inflammation can have both protective effects and collateral deleterious consequences for the host. The examples of successful therapies targeting inflammation underscore the importance of understanding inflammatory pathways to enable further therapeutic advances. involves systemic inflammatory responses, and frequent comorbidities are rheumatological or cardiovascular in nature 47 . In hidradenitis suppurativa, also known as acne inversa, a devastating skin disorder bearing characteristics of both autoinflammatory and autoimmune disorders, histopathology reveals heavy lesional deposits of TNF, IL-1b, IL-23 and IL-17, as well as activation of both CD4 + and CD8 + T cells 48 .
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Autoinflammatory syndromes
Autoinflammatory syndromes can be defined as disorders with abnormally increased inflammation, which are mediated predominantly by the cells and molecules of the innate immune system, with a substantial host predisposition. The enhanced inflammatory state encompasses the production of proinflammatory pyrogenic cytokines, particularly IL-1b, and hence fever and acute-phase responses are common prominent signs. From a theoretical viewpoint, autoinflammatory syndromes result from excessive production and/or biological activity of inflammatory mediators, or from a lack of endogenous inhibition. The prototypical condition associated with the latter is deficiency of IL-1Ra, in which a lack of inhibition of IL-1 bioactivity leads to excessive inflammation 49 . Other important syndromes are familial Mediterranean fever, cryopyrinopathies, and hyperimmunoglobulinemia D and periodic fever syndrome. An exaggerated IL-1b response is a hallmark of many autoinflammatory disorders, for which interference with IL-1 action is the preferred therapy 50 .
Cancer
All the usual components of the inflammatory response reside in the tumor microenvironment but often exhibit 'corrupted' functions. Cancer-related inflammation is a key component of the tumor microenvironment 51, 52 and includes inflammatory cells, especially tumor-associated macrophages, which affect all aspects of cancer including growth, genetic instability, angiogenesis and metastasis 53 . Tumor-associated macrophages contribute to cancer immunosuppression by producing prostaglandins, products of tryptophan metabolism, and by expressing checkpointblockade triggers (such as PD-L1 42 , thus predicting a decline in kidney function 43 . IL-1b contributes to tubular interstitial fibrosis, promotes tubular epithelial-myofibroblast transdifferentiation, cytokine gene expression, production of prostaglandin E2 by mesangial cells and interstitial fibrosis mediated by TGF-b (ref. 44) . Treatment with the IL-1 soluble receptor trap (rilonacept) decreases concentrations of C-reactive protein, improves dilation mediated by brachial artery flow and decreases vascular oxidative stress in people with chronic kidney disease 45 .
Inflammatory skin diseases
In atopic dermatitis, penetration of external stimuli (for example, allergens) through an impaired skin barrier leads to an exaggerated T H 2 response 46 . Local immunological imbalance causes further skin-barrier deterioration as IL-4 and IL-13 downregulate the expression of major skin-barrier genes such as filaggrins, thus leading to a vicious circle. In psoriasis, a T cell-driven disease with contributions of innate and adaptive immunity, inflammation is driven by signaling through NF-kB and T H 17-and T H 1-type cytokines, and therapies targeting TNF, IL-12/IL-23 and IL-17 have been found to be effective ( Table 1) . Psoriasis
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